摘要
目的观察莫西沙星治疗成人社区获得性肺炎(CAP)的有效性和安全性。方法 60例CAP患者随机分为治疗组和对照组各30例,治疗组给予莫西沙星治疗,对照组给予左氧氟沙星治疗,疗程均为1～2周。观察比较2组的临床疗效、细菌清除率及不良反应。结果治疗组总有效率为86.7%高于对照组的70.0%;治疗组细菌清除率为96.2%高于对照组的88.9%,差异均有统计学意义(P<0.05)。2组均未发生严重不良反应。结论莫西沙星用于成人CAP疗效显著,安全性高,值得临床推广应用。
Objective To observe the efficacy and safety of Moxifloxacin in the treatment of community-acquired pneumonia （CAP） in the adults patients. Methods 60 patients with CAP were randomly divided into treatment group and control group （n = 30 in each）. The treatment group was treated with Moxifloxacin, and the control group was treated with Levo- iloxacin,both groups were treated for 1 to 2 weeks. The clinical effect, bacterial clearance rate and adverse events were ob- served. Results The effective rate of the treatment group and control group were 86.7% and 70.0%. The bacterial clearance rate in the two groups were 96.2% and 88.9% respectively, and the difference was statistically significant （P 〈 0.05 ）. There were no severe drug-related adverse events in the two groups. Conclusion Moxifloxacin in the treatment of CAP in the adults patients is safe and effective ,and worthy in clinical application.
出处
《临床合理用药杂志》
2012年第5期15-16,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
肺炎
社区获得性
莫西沙星
左氧氟沙星
疗效
Community-acquired pneumonia
Moxifloxacin
Levofloxacin
Efficacy analysis
